Primary tumor resection in de novo stage IV breast cancer patients

Follette, Craig; Humphrey, C. A.; Amin, Amanda L.; Balanoff, Christa; Wagner, Jamie L.; Larson, Kelsey E.

doi:10.1111/tbj.13850

Cited by 1 publication

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the controversial role of surgical intervention in de novo metastatic breast cancer 22 – 25 , we comprehensively discussed the potential effects of surgical performance on the prognosis of LMBC. Surgical performance could prolong the OS of patients with LMBC independent of the molecular subtypes.…”

Section: Discussionmentioning

confidence: 99%

Clinical outcomes and a nomogram for de novo metastatic breast cancer with lung metastasis: a population-based study

Liu

2022

Sci Rep

View full text Add to dashboard Cite

To better understand the clinical characteristics of newly diagnosed lung metastatic breast cancer (LMBC) and quantify its prognosis, we retrieved data on patients with LMBC from the Surveillance, Epidemiology, and End Results database. Eligible patients were randomly assigned to training and validation cohorts (ratio 7:3) to establish a nomogram using the Cox proportional hazards regression model. In total, 4310 patients with LMBC were enrolled, including 52.4% (2259/4310) HR+/HER2−, 17.6% (757/4310) HR+/HER2+, 10.8% (467/4310) HR−/HER2+, and 19.2% (827/4310) HR−/HER2− subtype patients. Inclinations of lung and brain involvement in HR−/HER2+ and HR−/HER2− subgroups, liver involvement in the HER2 overexpressing subgroup, and bone involvement in the HR-positive subgroup were detected in the LMBC population. Regarding prognosis, HR+/HER2+ subtype patients presented the most favorable profile (mOS 35.0 months, 95% CI 30.1–39.9), while HR−/HER2− patients exhibited the worst (mOS 11.0 months, 95% CI, 10.0–11.9). A nomogram was developed in the training cohort and validated internally (C-index 0.70) and externally (C-index 0.71), suggestive of decent performance. This study assessed the clinical outcomes associated with molecular subtypes, metastatic patterns, and surgical intervention and provided a robust nomogram for the estimation of survival probabilities, which are promising for the management of LMBC in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical outcomes and a nomogram for de novo metastatic breast cancer with lung metastasis: a population-based study

Liu

2022

Sci Rep

View full text Add to dashboard Cite

show abstract

Primary tumor resection in de novo stage IV breast cancer patients

Cited by 1 publication

References 19 publications

Clinical outcomes and a nomogram for de novo metastatic breast cancer with lung metastasis: a population-based study

Clinical outcomes and a nomogram for de novo metastatic breast cancer with lung metastasis: a population-based study

Contact Info

Product

Resources

About